Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P07711
UPID:
CATL1_HUMAN
Alternative names:
Cathepsin L1; Major excreted protein
Alternative UPACC:
P07711; Q6IAV1; Q96QJ0
Background:
Procathepsin L, also known as Cathepsin L1 and Major excreted protein, is a thiol protease pivotal in lysosomal degradation, antigen processing, and bone remodeling. It facilitates the release of thyroid hormone thyroxine (T4) and processes proenkephalin into active neurotransmitters. Additionally, it plays a role in T cell selection, elastin degradation, and extracellular matrix regulation during inflammation. Its involvement in microbial infections includes aiding SARS-CoV and SARS-CoV-2 entry into host cells.
Therapeutic significance:
Understanding the role of Procathepsin L could open doors to potential therapeutic strategies.